keyword
MENU ▼
Read by QxMD icon Read
search

Active surveillance prostate

keyword
https://www.readbyqxmd.com/read/29028765/preventing-clinical-progression-and-need-for-treatment-in-patients-on-active-surveillance-for-prostate-cancer
#1
Hanan Goldberg, Zachary Klaassen, Thenappan Chandrasekar, Neil Fleshner
PURPOSE OF REVIEW: Active surveillance is an established treatment option for men with localized, low-risk prostate cancer (CaP). It entails the postponement of immediate therapy with the option of delayed intervention upon disease progression. The rate of clinical progression and need for treatment on active surveillance is approximately 50% over 15 years. The present review summarizes recent data on current methods, attempting to prevent clinical progression. RECENT FINDINGS: Patient selection for active surveillance is the first mandatory step required to lower progression...
October 11, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29026057/pathological-outcome-for-chinese-patients-with-low-risk-prostate-cancer-eligible-for-active-surveillance-and-undergoing-radical-prostatectomy-comparison-of-six-different-active-surveillance-protocols
#2
C F Tsang, J Hl Tsu, T Ct Lai, K W Wong, B Sh Ho, A Tl Ng, W K Ma, M K Yiu
INTRODUCTION: Active surveillance is one of the therapeutic options for the management of patients with low-risk prostate cancer. This study compared the performance of six different active surveillance protocols for prostate cancer in the Chinese population. METHODS: Patients who underwent radical prostatectomy for prostate cancer from January 1998 to December 2012 at a university teaching hospital in Hong Kong were reviewed. Six active surveillance protocols were applied to the cohort...
October 13, 2017: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/29023685/summary-statement-on-screening-for-prostate-cancer-in-europe
#3
Eveline A M Heijnsdijk, Chris H Bangma, Josep M Borràs, Tiago M de Carvalho, Xavier Castells, Martin Eklund, Josep A Espinàs, Markus Graefen, Henrik Grönberg, Iris Lansdorp-Vogelaar, Pim J van Leeuwen, Vera Nelen, Franz Recker, Monique J Roobol, Pieter Vandenbulcke, Harry J de Koning
The European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that Prostate-Specific Antigen (PSA) based screening results in a significant prostate cancer mortality reduction. Although there are concerns on overdiagnosis and overtreatment, it has been shown that the benefits can outweigh the harms if screening is stopped in older ages to prevent overdiagnosis. A limited screening program (for example screening at ages 55-59 years), including active surveillance for men with low-risk tumors, can even be cost-saving, compared with testing in an opportunistic setting in the wrong ages, as currently in Europe...
October 12, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29017178/cardiovascular-disease-risk-and-androgen-deprivation-therapy-in-patients-with-localised-prostate-cancer-a-prospective-cohort-study
#4
Reina Haque, Marianne UlcickasYood, Xiaoqing Xu, Andrea E Cassidy-Bushrow, Huei-Ting Tsai, Nancy L Keating, Stephen K Van Den Eeden, Arnold L Potosky
BACKGROUND: As androgen deprivation therapy (ADT) is increasingly being used in men with localised prostate cancer, our goal was to examine the association between ADT and the risk of cardiovascular disease (CVD). METHODS: We conducted a prospective cohort study using records of a large health-care system in California. The study included men with newly diagnosed localised prostate cancer (1998-2008) who initially underwent active surveillance (N=7637) and were followed through 2010...
October 10, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29016610/association-between-a-17-gene-genomic-prostate-score-and-multi-parametric-prostate-mri-in-men-with-low-and-intermediate-risk-prostate-cancer-pca
#5
Michael S Leapman, Antonio C Westphalen, Niloufar Ameli, H Jeffrey Lawrence, Phillip G Febbo, Matthew R Cooperberg, Peter R Carroll
BACKGROUND: We aimed to directly compare results from multi-parametric prostate MRI (mpMRI) and a biopsy-based 17-gene RT-PCR assay providing a Genomic Prostate Score (GPS) among individuals who were candidates for active surveillance with low and intermediate risk prostate cancer (PCa). PATIENTS AND METHODS: We evaluated the association between GPS results (scale 0-100) and endorectal mpMRI findings in men with clinically localized PCa. MR studies were reviewed to a five-tier scale of increasing suspicion of malignancy...
2017: PloS One
https://www.readbyqxmd.com/read/28990929/multiparametric-magnetic-resonance-imaging-for-active-surveillance-of-prostate-cancer
#6
Julie Y An, Abhinav Sidana, Peter L Choyke, Bradford Wood, Peter A Pinto, İsmail Barış Türkbey
Active surveillance has gained popularity as an acceptable management option for men with low-risk prostate cancer. Successful utilization of this strategy can delay or prevent unnecessary interventions - thereby reducing morbidity associated with overtreatment. The usefulness of active surveillance primarily depends on correct identification of patients with low-risk disease. However, current population-wide algorithms and tools do not adequately exclude high-risk disease, thereby limiting the confidence of clinicians and patients to go on active surveillance...
September 29, 2017: Balkan Medical Journal
https://www.readbyqxmd.com/read/28988963/defining-novel-and-practical-metrics-to-assess-the-deliverables-of-multiparametric-magnetic-resonance-imaging-ultrasound-fusion-prostate-biopsy
#7
Benjamin T Ristau, David Y T Chen, Jeffrey Ellis, Aseem Malhotra, Lyudmilla DeMora, Rosaleen B Parsons, Barton Milestone, Marion Brody, Rosalia Viterbo, Richard Greenberg, Marc Smaldone, Robert Uzzo, Jordan Anaokar, Alexander Kutikov
PURPOSE: Multiparametric magnetic resonance (mpMRI)/ultrasound targeted prostate biopsy (TB) is touted as a tool to improve prostate cancer care. Yet, the true clinical utility of TB over transrectal ultrasound-guided prostate biopsy (TRUS-B) has not been systematically analyzed. We introduce two metrics to better quantify and report the deliverables of TB. MATERIALS AND METHODS: We reviewed our prospective database containing patients who underwent simultaneous TB/TRUS-B...
October 5, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28988753/a-biopsy-based-17-gene-genomic-prostate-score-as-a-predictor-of-metastases-and-prostate-cancer-death-in-surgically-treated-men-with-clinically-localized-disease
#8
Stephen K Van Den Eeden, Ruixiao Lu, Nan Zhang, Charles P Quesenberry, Jun Shan, Jeong S Han, Athanasios C Tsiatis, Amethyst D Leimpeter, H Jeffrey Lawrence, Phillip G Febbo, Joseph C Presti
BACKGROUND: A 17-gene biopsy-based reverse transcription polymerase chain reaction assay, which provides a Genomic Prostate Score (GPS-scale 0-100), has been validated as an independent predictor of adverse pathology and biochemical recurrence after radical prostatectomy (RP) in men with low- and intermediate-risk prostate cancer (PCa). OBJECTIVE: To evaluate GPS as a predictor of PCa metastasis and PCa-specific death (PCD) in a large cohort of men with localized PCa and long-term follow-up...
October 5, 2017: European Urology
https://www.readbyqxmd.com/read/28988599/pathological-outcomes-in-men-with-prostate-cancer-who-are-eligible-for-active-surveillance
#9
Shu-Chi Wang, Cheng-Che Chen, Cheng-Kuang Yang, Siu-Wan Hung, Yee-Jee Jan, Yen-Chuan Ou
BACKGROUND: In order to prevent over treatment of prostate cancer and significant adverse effects after surgical intervention, active surveillance was suggested in low risk or very low risk patients. This study aimed to retrospectively analyze the adverse pathological results of candidates eligible for active surveillance. METHODS: A total of 904 patients underwent robot-assisted laparoscopic radical prostatectomy in this single institute, from 2005 to April 2014...
October 2, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28982830/communicating-risk-in-active-surveillance-of-localised-prostate-cancer-a-protocol-for-a-qualitative-study
#10
Frances Rapport, Anne Hogden, Howard Gurney, David Gillatt, Mia Bierbaum, Patti Shih, Kate Churruca
INTRODUCTION: One in five men is likely to receive a diagnosis of prostate cancer (PCa) by the age of 85 years. Men diagnosed with low-risk PCa may be eligible for active surveillance (AS) to monitor their cancer to ensure that any changes are discovered and responded to in a timely way. Communication of risk in this context is more complicated than determining a numerical probability of risk, as patients wish to understand the implications of risk on their lives in concrete terms. Our study will examine how risk for PCa is perceived, experienced and communicated by patients using AS with their health professionals, and the implications for treatment and care...
October 5, 2017: BMJ Open
https://www.readbyqxmd.com/read/28981735/pathological-and-oncological-features-of-korean-prostate-cancer-patients-eligible-for-active-surveillance-analysis-from-the-k-cap-registry
#11
Kyo Chul Koo, Kwang Suk Lee, Jae Yong Jeong, In Young Choi, Ji Youl Lee, Jun Hyuk Hong, Choung-Soo Kim, Hyun Moo Lee, Sung Kyu Hong, Seok-Soo Byun, Seung Hwan Lee, Koon Ho Rha, Byung Ha Chung
Background: A web-based multicenter Korean Prostate Cancer Database (K-CaP) was established to provide urologists with information on Korean prostate cancer (PCa) patients treated with radical prostatectomy (RP). We utilized the K-CaP registry to identify pathological features and oncological outcomes of Korean PCa patients eligible for active surveillance (AS). Methods: The K-CaP registry consisted of 6415 patients who underwent RP from May 2001 to April 2013 at five institutions...
October 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28972698/prognostic-value-of-urinary-pca3-during-active-surveillance-of-low-risk-prostate-cancer-in-patients-receiving-5%C3%AE-reductase-inhibitors
#12
Vincent Fradet, Paul Toren, Molière Nguile-Makao, Michele Lodde, Jérome Lévesque, Caroline Léger, André Caron, Alain Bergeron, Tal Ben-Zvi, Louis Lacombe, Frédéric Pouliot, Rabi Tiguert, Thierry Dujardin, Yves Fradet
OBJECTIVES: To determine the clinical performance of the urinary PCA3 test to predict the risk of Gleason grade re-classification among men receiving a 5α-reductase inhibitor during active surveillance for prostate cancer. PATIENTS AND METHODS: Patients with low-risk prostate cancer were enrolled in a prospective Phase II study of active surveillance complemented with prescription of a 5ARI. Repeat biopsy was performed within the first year and annually according to physician and patient preference...
October 3, 2017: BJU International
https://www.readbyqxmd.com/read/28962878/targeted-prostate-biopsy-in-the-era-of-active-surveillance
#13
REVIEW
Fuad F Elkhoury, Demetrios N Simopoulos, Leonard S Marks
Targeted prostate biopsy using magnetic resonance imaging (MRI) guidance is improving accuracy of prostate cancer (CaP) diagnosis. This new biopsy technology is especially important for men undergoing active surveillance, improving patient selection for enrollment and enabling precise longitudinal monitoring. MRI/US fusion biopsy allows for three functions not previously possible with US-guided biopsy: targeting of suspicious regions, template-mapping for systematic sampling, and tracking of cancer foci over time...
September 26, 2017: Urology
https://www.readbyqxmd.com/read/28960827/the-accuracy-of-patients-perceptions-of-the-risks-associated-with-localized-prostate-cancer-treatments
#14
Marie-Anne van Stam, Henk G van der Poel, Jochem R N van der Voort van Zyp, Corinne N Tillier, Simon Horenblas, Neil K Aaronson, J L H Ruud Bosch
OBJECTIVES: To assess localized prostate cancer (PC) patients' understanding of the differences in outcomes and risks of radical prostatectomy (RP), radiotherapy (RT), and active surveillance (AS), and to identify correlates of misperceptions. PATIENTS AND METHODS: We used baseline data (questionnaires completed after treatment information was provided but prior to treatment) of 426 newly diagnosed localized PC patients who participated (87% response rate) in a prospective, longitudinal, multicenter study...
September 28, 2017: BJU International
https://www.readbyqxmd.com/read/28959144/active-surveillance-of-prostate-cancer-current-state-of-practice-and-utility-of-multiparametric-magnetic-resonance-imaging
#15
Ridwan Alam, H Ballentine Carter, Jonathan I Epstein, Jeffrey J Tosoian
Active surveillance (AS) is an alternative to immediate intervention in patients with very low- and low-risk prostate cancer. Ongoing reports from multiple AS programs have consistently demonstrated a very low rate of metastasis and prostate cancerspecific mortality in appropriately selected patients. Accordingly, AS has been adopted by major clinical organizations as a safe and effective management strategy. Clinical focus has now shifted to identifying the optimal approach to selecting and monitoring patients...
2017: Reviews in Urology
https://www.readbyqxmd.com/read/28958194/active-surveillance-for-localized-prostate-cancer-update-of-a-prospective-single-center-cohort
#16
Mathias Thostrup, Frederik B Thomsen, Peter Iversen, Klaus Brasso
OBJECTIVE: The purpose of active surveillance (AS) is to reduce overtreatment of men with localized prostate cancer (PCa) without compromising survival. The objective of this study was to update a large Scandinavian single-center AS cohort. Furthermore, the use of curative treatment and subsequent risk of biochemical recurrence were investigated and compared in men with very low-risk, low-risk and intermediate-risk PCa in the cohort. MATERIALS AND METHODS: In total, 451 men were followed on AS and monitored with prostate-specific antigen (PSA) tests, digital rectal examinations and rebiopsies...
September 28, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28947084/patients-with-intermediate-risk-prostate-cancer-may-be-good-candidates-for-active-surveillance-con
#17
Jeffrey J Tosoian, H Ballentine Carter
No abstract text is available yet for this article.
September 22, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28947083/patients-with-intermediate-risk-prostate-cancer-may-be-good-candidates-for-active-surveillance-pro
#18
Martin G Sanda
No abstract text is available yet for this article.
September 22, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28942009/comparison-of-11-active-surveillance-protocols-in-contemporary-european-men-treated-with-radical-prostatectomy
#19
Sami-Ramzi Leyh-Bannurah, Pierre I Karakiewicz, Paolo Dell'Oglio, Alberto Briganti, Jonas Schiffmann, Raisa S Pompe, Guido Sauter, Thorsten Schlomm, Hans Heinzer, Hartwig Huland, Markus Graefen, Lars Budäus
BACKGROUND: The aim of this study was to compare 11 active surveillance (AS) protocols in contemporary European men treated with radical prostatectomy (RP) at the Martini-Clinic Prostate Cancer Center. PATIENTS AND METHODS: Analyzed were 3498 RP patients, from 2005 to 2016, who underwent ≥ 10 core biopsies and fulfilled at least 1 of 11 examined AS entry definitions. We tested proportions of AS eligibility, ineligibility, presence of primary Gleason 4/5, upstage, and combinations thereof at RP, as well as 5-year biochemical recurrence-free survival (BFS)...
August 31, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28941920/genomic-scores-are-independent-of-disease-volume-in-men-with-favorable-risk-prostate-cancer-implications-for-choosing-men-for-active-surveillance
#20
Yaw A Nyame, Dominic C Grimberg, Daniel J Greene, Karishma Gupta, Ganesh K Kartha, Ryan Berglund, Michael Gong, Andrew J Stephenson, Cristina Magi-Galluzzi, Eric A Klein
OBJECTIVE: To determine if disease volume at prostate biopsy correlates with genomic scores among men with favorable risk prostate cancer. METHODS: All men with NCCN very low (VLR) and low risk (LR) disease and OncotypeDx Prostate testing at our institution from 2013 to 2016 were identified. Volume of disease was characterized as percent of positive cores, number of cores with >50% involvement, largest involvement of any single core, and PSA density. Nonparametric testing was performed to compare the median genomic prostate score (GPS) and likelihood of favorable pathology (LFP) between quartiles of disease volume...
September 20, 2017: Journal of Urology
keyword
keyword
109735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"